MS HB1042

Establishes the "Right to Try Act" allowing licensed physicians to prescribe investigational drugs, biological products, or devices to terminally ill patients who have exhausted FDA-approved treatment options and relevant clinical trials

Defines eligible patients as those with a terminal illness or fatal disability who provide written informed consent documenting understanding of risks, including that the treatment could hasten death or cause unanticipated symptoms

Investigational drugs must have completed Phase 1 of FDA clinical trials but not yet received full approval; Schedule I controlled substances are excluded

Manufacturers may provide investigational treatments for free or at cost, but health insurers, the Mississippi Department of Corrections, hospitals, and nursing homes are not required to cover or provide these treatments

Grants civil immunity to physicians, pharmacists, and manufacturers from liability for prescribing or providing investigational treatments, except in cases of gross negligence or willful misconduct, and prohibits licensing boards from taking adverse action against their licenses